ZYN002

Zynerba Pharmaceuticals Adds Autism, DiGeorge Syndrome To Pipeline

Zynerba Pops On Positive Phase 2 Data For ZYN002 In Fragile X

Zynerba Pharmaceuticals Shares Volatile After Epilepsy Study Results

Zynerba Pops On Positive Phase 2 Data For ZYN002 In Fragile X

Zynerba Pharmaceuticals Shares Volatile After Epilepsy Study Results

Analyst Upgrades Zynerba, Encouraged By Prospects For Fragile X Phase 2 Study

Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain

Analyst Upgrades Zynerba, Encouraged By Prospects For Fragile X Phase 2 Study

Zynerba's Recent Results Revitalize The Bull Case, But Risks Remain

How Important Is Zynerba's ZYN002 For Children Suffering From Fragile X Syndrome?

Is GW Pharma Now The Future Of Cannabis-Based Drugs?

ZYN002 Recent News

Zynerba's Clinical-Trial Miss Devastates Stock Price

Canton Fitzgerald Reiterates Overweight Rating, $28 Price Target On Zynerba

What Analysts Expect For Zynerba's Upcoming Wave Of Data

Catalysts Growing Like Weeds For Zynerba Next Quarter

It's High Time For Zynerba Positives: Investors Await 3 Key Mid-Stage Trial Reads On Cannabidiol ZYN002

Zynerba Could See 3 Clinical Study Catalysts In 2017's First Half

Zynerba CEO Talks Election, Balance Sheet And Huge Osteoarthritis Market Potential

A Higher Probability For Success Is Not Baked Into Zynerba's Valuation

GW Pharma's Epidiloex Data Is Good News For Zynerba